At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Topical beremagene geperpavec +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
In Brief
A Phase 2 clinical trial evaluating Topical beremagene geperpavec and Placebo gel for Dystrophic Epidermolysis Bullosa. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study was conducted to assess the safety and efficacy of topical Beremagene Geperpavec (KB103, HSV1-COL7) on DEB patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDystrophic Epidermolysis Bullosa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedMay 24, 2018
Enrollment StartMay 6, 2018
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.1 years ago
Interventions
Topical beremagene geperpavecbiological
Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Placebo gelbiological
Placebo gel